In vitro carboplatin-mesna interaction in aqueous solution, human plasma and urine.

Obrocea, Mihail; Nassim, M A; Molepo, M.; Shirazi, Farshad H.; Gallant, Gilles; Dulude, Hélène; Vincent, Maxime; Stewart, Douglas; Goel, Richa

doi:10.3892/or.5.6.1493

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 It has also been used as a protective drug to reduce the nephrotoxicity of carboplatin. 5 However, the metal complexes with this simple thiol have been poorly studied. Previous reports are limited to the anti-tumor activity of the organotin() compounds and to the interaction with some transition metals in vitro and in vivo.…”

Section: Introductionmentioning

confidence: 99%

Rhenium and technetium-99m complexes with coenzyme M (MESNA)

Martín

Piera²,

Mazzi

et al. 2003

Dalton Trans.

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Rhenium and technetium-99m complexes with coenzyme M (MESNA)

Martín

Piera²,

Mazzi

et al. 2003

Dalton Trans.

View full text Add to dashboard Cite

Influence of Mesna on the Pharmacokinetics of Cisplatin and Carboplatin in Pediatric Cancer Patients

Kangarloo

Gangopadhyay

Syme

et al. 2004

View full text Add to dashboard Cite

Mesna, a reactive thiol, often encounters cisplatin and carboplatin in combination protocols involving oxazaphosphorines and platinum drugs. This co-administration might be unfavorable based on the inactivation of platinum drugs by thiol groups in vitro. We investigated whether mesna influences the pharmacokinetics of platinum drugs when co-administered with cisplatin or carboplatin. The pharmacokinetics of platinum drugs were investigated in 18 pediatric patients receiving either cisplatin or carboplatin in a combination with or without mesna. In cisplatin patients, a decrease in the distribution clearance of total platinum was observed when mesna was co-administered (CLd, 2.2 +/- 0.1 mL/min.kg; n = 3), compared to cisplatin without mesna (CLd, 4.8 +/- 1.5 mL/min.kg; n = 5) (p = 0.029, t-test). This might have been caused by an influence of mesna in slowing down the protein binding of cisplatin since a trend (p = 0.057) in prolonged distribution half-life of total platinum was also observed when mesna was present (t(1/2a) 65 +/- 21 min; n = 3) compared to cisplatin without mesna (t(1/2a), 32 +/- 18 min; n = 5). However, the impact of these changes on the area under the concentration time curve (AUC), total clearance (CLt), and volume of distribution (V) for total platinum and ultrafilterable platinum species was hardly noticeable. In carboplatin patients, when mesna was co-administered: AUC (2.5 +/- 0.4 mg.min/mL.400 mg/m2; n = 5) CLt, (6.8 +/- 5.1 mL/min.kg; n = 6), and V (0.7 +/- 0.4 L/kg; n = 6) for ultrafilterable platinum species were not significantly different from when carboplatin were administered without mesna: AUC (2.3 +/- 1.3 mg.min/mL.400 mg/m2; n = 4), CLt (5.8 +/- 4.6 mL/min.kg; n = 5), and V (1.1 +/- 1.1 L/kg; n = 5). Hence, mesna does not significantly influence the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.

show abstract

In vitro carboplatin-mesna interaction in aqueous solution, human plasma and urine.

Cited by 2 publications

References 0 publications

Rhenium and technetium-99m complexes with coenzyme M (MESNA)

Rhenium and technetium-99m complexes with coenzyme M (MESNA)

Influence of Mesna on the Pharmacokinetics of Cisplatin and Carboplatin in Pediatric Cancer Patients

Contact Info

Product

Resources

About